Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
Protagenic Therapeutics (PTIX) reported a net loss of approximately $1.5 million for Q2 2021, up from $0.6 million in Q2 2020. Operating and administrative expenses rose significantly, with general and administrative costs reaching about $1.2 million, compared to $0.4 million the prior year. The company closed a $13.2 million public offering and plans to refile its IND application for PT00114 in Q4 2021, with a Phase I/IIa study set to initiate in Q1 2022. As of June 30, 2021, PTIX had $11.9 million in cash and approximately 16.6 million shares outstanding.
- Closed a $13.2 million public offering.
- Plans to refile IND application for PT00114 in Q4 2021.
- Upcoming Phase I/IIa study for PT00114 expected to start in Q1 2022.
- Net loss increased to approximately $1.5 million in Q2 2021 from $0.6 million in Q2 2020.
- General and administrative expenses rose to around $1.2 million from $0.4 million year-over-year.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021.
Recent Highlights
- Closed a
$13.2 million public offering - Up listed to the Nasdaq Capital Market
- Hosted a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction
- Received FDA comment to provide clinical sites with ready-to-inject clinical vials of PT00114; to result in IND refiling in the fourth quarter
“During the second quarter and year to date, we made important progress towards advancing PT00114 into the clinic, in order to treat stress-related neuropsychiatric disorders which afflict a growing patient population,” said Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics. “We have a clear clinical path toward major indications. We anticipate rapid efficacy and safety readouts in the first half of 2022.”
Anticipated Upcoming Milestones
- Q4 2021: Re-filing of IND application for PT00114
- Q1 2022: Initiation of Phase I/IIa study for PT00114
- 1H 2022: Initial Data Readout of Phase I/IIa study
Financial Results for the Second Quarter Ended June 30, 2021:
- Net loss attributable to common stockholders for the quarter ended June 30, 2021 was approximately
$1.5 million , compared to approximately$0.6 million for the quarter ended June 30, 2020. - Research and development expense totaled approximately
$0.1 million for the quarter ended June 30, 2021, compared to approximately$0.1 million during the quarter ended June 30, 2020. - General and administrative expense was approximately
$1.2 million for the quarter ended June 30, 2021, compared to approximately$0.4 million during the quarter ended June 30, 2020. - On April 29, 2021, the company closed on an underwritten public offering of 3,180,000 units at a public offering price of
$4.15 per unit. Each unit was comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable at a price of$4.98 per share and will expire five years from issuance. The common stock and warrants comprising the units separated upon closing of the offering and were issued separately. - As of June 30, 2021, the Company had cash and cash equivalents of approximately
$11.9 million . - As of August 16, 2021, the Company had approximately 16.6 million common shares outstanding.
Select Financial Information
Protagenic Therapeutics, Inc., and Subsidiary
Cash, Cash Equivalents, and Current Assets
(In U.S. Dollars)
(Unaudited)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | 11,932,973 | $ | 671,091 | ||||
| Prepaid expenses | 129,167 | 208,156 | ||||||
| TOTAL CURRENT ASSETS | 12,062,140 | 879,247 | ||||||
| TOTAL ASSETS | $ | 12,062,140 | $ | 879,247 | ||||
Consolidated Statements of Operations
(In U.S. Dollars)
(Unaudited)
| For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| OPERATING AND ADMINISTRATIVE EXPENSES | ||||||||||||||||
| Research and development | 140,592 | 52,008 | 732,943 | 117,967 | ||||||||||||
| General and administrative | 1,168,241 | 436,935 | 1,782,080 | 891,712 | ||||||||||||
| TOTAL OPERATING AND ADMINISTRATIVE EXPENSES | 1,308,833 | 488,943 | 2,515,023 | 1,009,679 | ||||||||||||
| LOSS FROM OPERATIONS | (1,308,833 | ) | (488,943 | ) | (2,515,023 | ) | (1,009,679 | ) | ||||||||
| OTHER (EXPENSE) INCOME | ||||||||||||||||
| Interest income | 227 | 93 | 232 | 477 | ||||||||||||
| Interest expense | (239,190 | ) | (54,944 | ) | (323,127 | ) | (93,930 | ) | ||||||||
| Change in fair value of derivative liability | - | (23,560 | ) | 83,670 | 37,189 | |||||||||||
| TOTAL OTHER INCOME (EXPENSES) | (238,963 | ) | (78,411 | ) | (239,225 | ) | (56,264 | ) | ||||||||
| LOSS BEFORE TAX | (1,547,796 | ) | (567,354 | ) | (2,754,248 | ) | (1,065,943 | ) | ||||||||
| INCOME TAX EXPENSE | - | - | - | - | ||||||||||||
| NET LOSS | $ | (1,547,796 | ) | $ | (567,354 | ) | $ | (2,754,248 | ) | $ | (1,065,943 | ) | ||||
| COMPREHENSIVE LOSS | ||||||||||||||||
| Other Comprehensive Loss - net of tax | ||||||||||||||||
| Foreign exchange translation income (loss) | 482 | 1,084 | 973 | (1,335 | ) | |||||||||||
| TOTAL COMPREHENSIVE LOSS | $ | (1,547,314 | ) | $ | (566,270 | ) | $ | (2,753,275 | ) | $ | (1,067,278 | ) | ||||
| Net loss per common share - Basic and Diluted | $ | (0.11 | ) | $ | (0.06 | ) | $ | (0.22 | ) | $ | (0.10 | ) | ||||
| Weighted average common shares - Basic and Diluted | 14,487,277 | 10,261,419 | 12,488,906 | 10,261,419 | ||||||||||||
See accompanying notes to these unaudited consolidated financial statements in our Form 10-Q filed with the SEC August 16, 2021
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders. For more information, visit http://www.protagenic.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Protagenic Therapeutics’ product candidates and pre-clinical development and clinical trial plans and activities. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the pre-clinical testing and eventual clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in pre-clinical and clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors described under the Risk Factors section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.. Protagenic Therapeutics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Protagenic undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Analyst Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
213-260-4342
alex.arrow@protagenic.com
Media Contact:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
FAQ
What are the financial results of Protagenic Therapeutics for Q2 2021?
What is the status of PT00114 as of August 2021?
How much cash does Protagenic Therapeutics have as of June 30, 2021?
How many common shares are outstanding for PTIX as of August 2021?
What were the research and development expenses for Protagenic in Q2 2021?
